Inflammatory markers can predict pulmonary exacerbations of cystic fibrosis

D. Caudri (Rotterdam, Netherlands)

Source: International Congress 2017 – Cystic fibrosis: monitoring and biomarkers
Session: Cystic fibrosis: monitoring and biomarkers
Session type: Oral Presentation
Number: 4400
Disease area: Paediatric lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Caudri (Rotterdam, Netherlands). Inflammatory markers can predict pulmonary exacerbations of cystic fibrosis. 4400

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Differences in clinical features and biomarkers of subsequent acute cystic fibrosis pulmonary exacerbations - Analysing exacerbations as separate entities
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013


Predictive factors for severe pulmonary exacerbations in patients with cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 715s
Year: 2006

Biomarkers of early relapse of pulmonary exacerbation in cystic fibrosis adult patients
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013


Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis
Source: ERJ Open Res, 4 (1) 00111-2017; 10.1183/23120541.00111-2017
Year: 2018



Mechanisms and markers of airway inflammation in cystic fibrosis
Source: Eur Respir J 2002; 19: 333-340
Year: 2002



Inflammatory markers in cystic fibrosis patients with different values of pulmonary function tests
Source: Eur Respir J 2002; 20: Suppl. 38, 528s
Year: 2002

Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013


Novel biomarkers in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013

Acute exercise in cystic fibrosis patients increases neutrophilic pulmonary inflammation
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new basic and clinical physiology research
Year: 2012


Early detection of pulmonary exacerbations in children with cystic fibrosis by electronic home monitoring of symptoms and lung function
Source: International Congress 2016 – Cystic fibrosis: monitoring and management
Year: 2016


Season dynamics of inflammatory markers in patients with cystic fibrosis lung disease
Source: Eur Respir J 2002; 20: Suppl. 38, 528s
Year: 2002

Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013

Frequency and pathogenicity of rhinovirus associated pulmonary exacerbations in patients with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013

Pulmonary arterial enlargement is a predictor of higher risk of exacerbations in non-cystic fibrosis bronchiectasis patients
Source: Virtual Congress 2021 – Bronchiectasis
Year: 2021


Differences of acute exacerbations in idiopathic pulmonary fibrosis compared to other fibrotic lung diseases
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019

Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis
Source: International Congress 2016 – ILD pathogenesis
Year: 2016


Prognostic significance of selected biomarkers in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease
Source: International Congress 2014 – Sarcoidosis
Year: 2014


Changes in the small airways in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013

Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016